Foresee Pharma advances MAA filing for cancer candidate

6 February 2017

Taiwan-based Foresee Pharmaceuticals (TWO: 6576) has announced progress in filing for European approval for its investigational prostate cancer drug.

The company has successfully concluded its scientific advice discussions with German Federal Institute for Drugs and Medical Devices (BfArM) on key regulatory and development issues relating to a Marketing Authorization Application (MAA) submission of FP-001, Leuprolide Mesylate Injectable Suspension (LMIS) 50mg, a six-month depot of leuprolide mesylate for subcutaneous injection.

Foresee has very recently completed a global registration study with FP-001 LMIS 50mg and plans to seek regulatory approvals in the USA and several major European Union countries.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK